Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Duligotuzumab |
Synonyms | |
Therapy Description |
Duligotuzumab (MEHD7945A) is a two-in-one antibody that inhibits both ERBB3 (HER3) and EGFR signaling, resulting in greater efficacy than monospecific HER antibodies against multiple tumor models (PMID: 22014573, PMID: 29506988). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Duligotuzumab | MEHD7945A | EGFR Antibody 60 HER3 (ERBB3) Antibody 23 | Duligotuzumab (MEHD7945A) is a two-in-one antibody that inhibits both ERBB3 (HER3) and EGFR signaling, resulting in greater efficacy than monospecific HER antibodies against multiple tumor models (PMID: 22014573, PMID: 29506988). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01652482 | Phase II | Cetuximab Duligotuzumab Fluorouracil + Irinotecan + Leucovorin | A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | Completed | USA | ROU | NZL | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 0 |
NCT01577173 | Phase II | Cetuximab Duligotuzumab | A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck | Completed | USA | ROU | ITA | HUN | GBR | FRA | ESP | DEU | BGR | BEL | AUS | 0 |